Departments of Orthopedics and Cell Biology (T.S., V.G., R.B., W.C.H.), Yale University School of Medicine, New Haven, Connecticut 06520; Department of Endocrinology (T.S., A.M.F.), Hospital Bergmannsheil, Ruhr University Bochum, 44789 Bochum, Germany; and Department of Molecular Pharmacology (M.P., D.F.M.), Division of Biology and Medicine, Brown University, Providence, Rhode Island 02912
Address all correspondence and requests for reprints to: Dr. William C. Horne, Yale University School of Medicine, Department of Orthopaedics, P.O. Box 208044, New Haven, Connecticut 06520-8044. E-mail: william.horne{at}yale.edu.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The CTR [calcitonin (CT) receptor] belongs to Class B of G protein-coupled receptors (GPCR) and was first cloned in 1991 (5). Recently the CTR was also identified as an amylin receptor when coexpressed with receptor activity modifying proteins (also known as RAMPs) (6). Knockout of the CTR gene in mice is embryonic lethal by a yet unidentified mechanism (7). GPCRs comprise the largest superfamily of cell receptors and are involved in the translation of various extracellular signals to the intracellular compartment. They mediate response to the majority of known hormones, neurotransmitters, and neuromodulators and members function as sensors for extracellular ions, light, and pheromones. They serve as ligand-regulated guanine nucleotide exchange factors for heterotrimeric GTP-binding proteins, which in turn regulate several downstream effectors. The GPCRs share a general topology, with an extracellular N terminus followed by seven transmembrane domains (TMDs) connected via luminal/extracellular and cytoplasmic loops and a cytoplasmic C terminus and, within classes, a significant conservation of the TMDs.
Numerous alternatively spliced variants of the CTR have been described. The most common isoform in all species corresponds to the sequence originally cloned from porcine cells (5) and the rodent C1a isoform (8). Cloning of the rabbit CTR by our group revealed a splice variant with a deletion of exon 13, designated CTRe13, which encodes the C-terminal part of the seventh TMD (9). The
e13 variant showed less production of inositol phosphates, no Erk phosphorylation, and a decreased cAMP response to salmon and human CT stimulation (9, 10, 11). Recently, we demonstrated that some of these findings are caused by the fact that the
e13 variant is poorly expressed on the cell surface (11). Moreover, we demonstrated that the CTR forms homodimers and C1a/
e13-heterodimers and that the coexpression of the two isoforms results in decreased cell surface expression of the C1a isoform, that is, the
e13 isoform exerts a dominant-negative effect on CTR signaling (11). Interestingly, the exon encoding the C-terminal 14 amino acids of TM 7 is highly conserved in Class B GPCR genes. Spliced variants with the deletion of the same 14 amino acids as in the
e13 variant of the CTR have been described for three other members of the receptor family, the CRH-R1 (CRH receptor) (12), the vasoactive intestinal peptide receptor (VPAC2) (13) and the PTH/PTHrP receptor (14).
The deletion of 14 amino acids from the distal part of the seventh TMD reduces the hydrophobicity of the residual sequence that follows the third extracellular loop and might compromise the ability of that sequence to anchor in the lipid bilayer, leading to a 6-TMD receptor with a luminal/extracellular C-terminal domain. The absence of either the seventh TMD or the cytoplasmic tail could affect the transport of the receptor to the cell surface or cause the retention of coexpressed C1a isoforms within the cell. We therefore asked how the absence of the amino acids encoded by exon 13 would affect the ability of the seventh TMD to insert into the lipid bilayer, and examined the properties of CTR constructs that lack only the C terminus or both the C terminus and the seventh TMD.
We show here that the lack of the distal part of the seventh TMD in the e13 isoform results in a protein segment that fails to segregate into the lipid membrane phase, leading to a luminal/extracellular C terminus. A CTR construct that lacked only the cytoplasmic C-terminal domain showed identical characteristics as
e13 in terms of intracellular localization, reduced cell surface expression, lack of mobilization of intracellular calcium, and failure to activate Erk, but failed to inhibit the cell surface expression of the C1a isoform. In contrast, a CTR construct that lacked the entire seventh TMD and C terminus inhibited cell surface expression of the C1a isoform, in a manner similar to the effect of
e13. We conclude that the cytoplasmic C-terminal tail is necessary for attaining normal levels of cell surface expression of the CTR, mobilization of intracellular calcium, and MAPK activation, whereas the absence of the seventh TMD is responsible for the dominant-negative effect of the CTR
e13 isoform.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The secondary shift values of the H protons, averaged over triplets of amino acids, provided a first evidence of secondary structure for the two receptor domains examined here. As illustrated in Fig. 1A
, both CTR (367405) (lower panel) and CTR(362412,
e13) (upper panel) have helical regions, identified by a negative secondary shift (resonances shifted to high field relative to the corresponding random-coil values). For the
e13 peptide, two helices extending from residue 365380 and 399412 subtend the region of the exon 13 deletion (residues 384397). The results for CTR (367405) clearly indicate that the residues corresponding to exon 13 adopt a helical structure, in accordance with the putative assignment of the seventh TMD.
|
To examine the ability of the peptides to partition into a lipid bilayer, we measured the change in 1H signal intensity that was induced by titration with 16-doxylstearic acid. 16-Doxylstearic acid places the nitroxide radical near the center of the zwitterionic micelle, and is therefore expected to significantly affect only those residues in the hydrophobic core. For CTR (367405) there was a significant decrease in 1H signal intensity for the central portion of the peptide, corresponding to the residues coded by exon 13 (Fig. 1B). This clearly indicates that the putative seventh TMD of the CTR, including the residues coded by exon 13, passes through the micelle. In stark contrast, only a small background broadening was observed throughout the sequence of the
e13 peptide (data not shown), in agreement with the entire molecule lying at the surface. Consistent with this observation, addition of 5-doxylstearic acid, which places the nitroxide radical at the level of the phosphate head-groups, produced a noticeable decrease in NMR signal intensity of
e13 (data not shown). The 5-doxylstearic acid-induced relaxation pattern corresponds to the periodicity of the two
-helices lying on the micelle surface, as previously observed for domains of another receptor (15). To examine the energetics of the conformations and topological arrangements, extensive molecular dynamics (MD) simulations were carried out for the receptor domains. The starting structure was placed at the water/decane interface with a topological orientation corresponding to results from the 5- and 16-doxyl stearate titration. The starting topological orientation is preserved during the MD simulation, showing the contemporary agreement of the experimentally derived structure and topological orientation, with the partition between the hydrophobic/hydrophilic phases and a low energy conformation.
The NMR analysis of the peptide conformation suggested that the absence of the sequence encoded by exon 13 leads to the loss of a functional seventh TMD and therefore an extracellular C-terminal domain of the e13 isoform. We therefore examined the locations of the C-terminals of the C1a and
e13 isoforms. C-terminally green fluorescent protein (GFP)-tagged constructs of the two isoforms were expressed in human embryonic kidney (HEK) 293 cells, and the cells were analyzed for the presence of extracellular GFP by fluorescence-activated cell sorter (FACS) analysis using anti-GFP antibody, as described in Materials and Methods. As expected, the cell-associated fluorescence of the cells transfected with the C1a isoform (Fig. 2
, lower panel) was the same in preparations stained with anti-GFP and those stained with secondary antibody only, indicating that the C-terminal of the C1a isoform is intracellular. In contrast, when the cells expressed the
e13 isoform (Fig. 2
, upper panel), the anti-GFP-dependent fluorescence (dark trace) of all the cells was slightly increased relative to the fluorescence of cells stained with secondary antibody only (light trace), and the fluorescence of a small population of the cells was increased by about 5- to 10-fold. These results suggest that the C-terminal domains of the small number of
e13 receptors that reach the cell surface are located extracellularly.
|
|
|
|
The Absence of the Seventh TMD Is Responsible for the Dominant-Negative Effect of the e13 Isoform on the Surface Expression of the C1a Isoform
We previously reported that the e13 isoform exerts a dominant-negative effect on CTR signaling by inhibiting the cell surface expression of the C1a isoform, and hypothesized that the heterodimerization of the C1a isoform with the
e13 isoform leads to the retention of the C1a isoform in an intracellular compartment (11). We therefore sought to determine whether coexpression of either or both of the C-terminally truncated C1a
397 and C1a
374 mutants with the C1a isoform would reduce the surface expression of the C1a isoform. We first examined the abilities of the C-terminally truncated CTR constructs to heterodimerize with the C1a isoform because dimerization is presumably a requirement for the dominant-negative effect of the
e13 isoform on the cell surface expression of the C1a isoform. HEK 293 cells were cotransfected with a FLAG-tagged C1a construct and with GFP-tagged C1a,
e13, C1a
397, or C1a
374 CTR constructs. Both the C-terminally truncated GFP-tagged CTR constructs were coimmunoprecipitated with the FLAG-tagged C1a isoform (Fig. 6
), indicating that like the
e13 isoform, they bind to the C1a isoform.
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Comparing the e13 isoform with C-terminally truncated CTR constructs demonstrates that the absence of a cytoplasmic C-terminal domain and a seventh TMD have different functional consequences: absence of the cytoplasmic C-terminal tail causes a strong reduction of the expression of the receptor on the cell surface and the inability to mobilize intracellular calcium and activate Erk, whereas the absence of the seventh TMD confers the dominant-negative effect of the
e13 isoform on the cell surface expression and signaling of the C1a isoform. The intracellular retention of the
e13 isoform is not reduced by culturing the cells at a lower temperature, as is true for some mutated membrane proteins (17, 18), consistent with the conclusion that the luminal/extracellular location of the normally cytoplasmic C-terminal domain is responsible for the inefficient translocation of the
e13 isoform to the cell surface.
To our knowledge, no GPCR with only six TMDs and a luminal/extracellular C terminus has been previously described, although naturally occurring splice isoforms similar to the CTRe13 isoform have been reported for three other class B GPCRs: CRH-R1, VPAC2, and the PTH/PTHrP receptor (12, 13, 14), and it is likely that the conformations of these splice isoforms relative to the membrane are similar to that of the CTR
e13 isoform. There are, however, several reports of the functional consequences of the absence of cytoplasmic tails of GPCRs. The effects vary, depending on the GPCR examined. The GnRH receptor is the only naturally occurring GPCR that completely lacks a cytoplasmic C-terminal tail. The GnRH receptor does not show rapid desensitization and the rates of internalization are slow relative to other GPCRs, properties that correlated with the absence of a cytoplasmic tail (19). C-terminal truncation mutants have been generated for various GPCRs, with various receptor-specific results: a reduction of ligand-induced internalization (20, 21), an increase in the activation of signaling (22), or no apparent effect on trafficking and signaling of the GPCR (23, 24). Our data demonstrate that the absence of a cytoplasmic C-terminal tail on the rabbit CTR significantly reduces the transport of the receptor to the cell surface, presumably due to the presence in the C-terminal tail of an amino acid motif that links the CTR to protein components of the transport mechanism, possibly filamin (16). The
e13 isoform retains all the amino acids present in the cytoplasmic tail, but an extracellular location of the C terminus would render that putative binding site inaccessible to intracellular proteins. Amino acid motifs that may be involved in the transport of other GPCRs to the cell surface have been described (25, 26), but none of them is present in the CTR.
The decrease in cAMP production in the cells transfected with the e13, C1a
397, or C1a
374 receptors (to 6080% of the cAMP production in the C1a-expressing cells at 1 nM and 10 nM sCT) is not proportional to the marked reduction in the numbers of receptors on the cell surface, raising a question of whether the receptors with the truncations or deletion couple more efficiently to adenylyl cyclase than the C1a receptor. Other studies have shown that the coupling of human and porcine CTRs to adenylyl cyclase is quite sensitive to changes in the cytoplasmic domains. The maximum cAMP production mediated by an isoform of the human CTR that contains a 16-residue insert in the first cytoplasmic loop (27) is about 30% less than that of the human CTR isoform that is equivalent of the C1a isoform, whereas the EC50 is about 100-fold higher (28). Like the rabbit
e13 isoform, the human isoform with the loop 1 insert fails to induce a change in [Ca2+]i. Progressive truncation of the porcine receptor cytoplasmic C-terminal domain changes the coupling to adenylyl cyclase in a complex manner; truncating after residues 399 (near the cytoplasmic face of the membrane) or 438 eliminates 9599% of the cAMP production, whereas an intermediate truncation after residue 418 is essentially indistinguishable from the intact receptor (29). Finally, replacing the cytoplasmic domains of the insert-containing human CTR isoform with various combinations of the homologous domains of the porcine receptor, which in some cases changes as few as four or five residues, results in changes in coupling to adenylyl cyclase that differ by as much as 4-fold and are in some cases unique to the specific combination of domains exchanged (30). In all of these studies, the changes in coupling to adenylyl cyclase were not correlated with changes in the coupling to phospholipase C.
A possible alternative explanation for the apparently increased coupling efficiency of the e13 isoform to adenylyl cyclase is suggested by the relative ligand binding and dose-response curves of the rabbit C1a isoform (9). Nearly 50% of the maximal cAMP response occurs at a CT concentration (0.01 nM) at which little binding is detected, demonstrating that a substantial cAMP response can be achieved by activating a relatively small number of receptors, even in the case of the unspliced C1a isoform. Elucidating the reasons for the differences in the apparent molar coupling efficiency of the CTR isoforms is the goal of future investigation.
In contrast to the ability of the e13, C1a
397, and C1a
374 receptors to couple to adenylyl cyclase, none of these constructs mediated the mobilization of intracellular calcium or Erk phosphorylation by CT when expressed alone. Neither 1 nM nor 10 nM sCT elicited a calcium response, indicating that the effect is not simply a change in the potency of the response. [We previously found that even 10 µM sCT failed to induce the activation of phospholipase C-catalyzed production of inositol phosphates by the
e13 isoform (9).] These results indicate that activation of G
s is at least partly independent of the C-terminal tail of the CTR, but that mobilization of intracellular calcium via activation of G
q and phospholipase C requires the presence of a cytoplasmic C-terminal domain. Similar findings have been reported for another GPCR, the
-opioid receptor (31), suggesting that at least some GPCRs share this structural requirement for activation of G
q and phospholipase C. The partial dependence of the CTR-mediated activation of Erk on G
i (32) suggests another possible reason for the absence of Erk phosphorylation when the cytoplasmic tail of the CTR is absent. Coupling of the ß2-adrenergic receptor to G
i was recently found to be induced by protein kinase A-dependent phosphorylation of the receptor, which switches the coupling specificity of the activated receptor from G
s to G
i (33). If a similar mechanism regulates the coupling of the CTR to G
i, the absence of a potential protein kinase A target site (residue 401) in the proximal C-terminal tail could prevent the induction of coupling of the CTR to G
i and activation of Erk. On the other hand, the presence of some pertussis toxin-insensitive activation of Erk by the CTR (32) suggests that the cytoplasmic C terminus of the CTR also activates another mechanism that stimulates Erk.
Our data clearly demonstrate that the absence of the seventh TMD in e13 and C1a
374 is responsible for their dominant-negative effect on the cell surface expression of the C1a isoform, but the mechanism remains to be elucidated. Removing the seventh TMD from its usual position in the cluster of transmembrane helices may expose a cryptic endoplasmic reticulum retention signal or otherwise make it appear that the receptor is misfolded, thereby activating a mechanism that prevents the transport of the receptor to the cell surface. Further investigation will be required to elucidate the mechanism.
Several pieces of evidence suggest that the generation of the e13 isoform by alternative splicing is a physiologically significant mechanism for modulating the response of CTR-expressing cells to CT. The
e13 isoform is found in all tissues that express the CTR. These include classic CT target tissues (brain, kidney, and osteoclasts) where CTR expression is relatively high, as well as lung and skeletal muscle, which are not typically thought of as responding to CT and contain significantly lower levels of CTR mRNA (9). The proportion of
e13 mRNA varies from 1015% in brain, kidney, and osteoclasts to 60% or more in muscle and lung (9). Analysis of the relative expression levels in individual osteoclasts (11) revealed that the ratio of the two isoforms is highly variable even in a single cell type, with some cells expressing mostly the C1a mRNA, others expressing mostly the
e13 mRNA and still others expressing both mRNAs in various proportions. Together, the change in the coupling properties of the alternatively spliced
e13 isoform and its ability to reduce the number of coexpressed C1a receptors at the cell surface indicate that a cell can regulate both the nature and the intensity of CT-induced signaling by altering the relative numbers of the two isoforms that are expressed. Elucidation of the way in which this splicing event is regulated could yield important insights into the physiology of CT. Moreover, because similar splice isoforms have been described for other members of the CTR family [the CRH-R1 (12), the VPAC2 vasoactive intestinal peptide receptor (13) and the PTH/PTHrP receptor (14)], alternative splicing of exon 13 in class B G protein-coupled receptors is likely to have a significance beyond the CTR.
In summary, we demonstrate for the first time the existence of a naturally occurring six TMD receptor derived from a splice variant of the CTR gene. The consequent luminal/extracellular localization of the normally cytoplasmic C-terminal domain results in markedly reduced levels of the receptor at the cell surface and prevents the ligand-induced mobilization of intracellular calcium and activation of Erk. However, the absence of a properly localized seventh TMD is responsible for the dominant-negative effect of the e13 isoform on cell surface expression and signaling by the common C1a isoform, demonstrating a prominent role of a seventh TMD in the regulation of trafficking of a GPCR.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Peptide Synthesis
Peptides CTR (367405), consisting of residues 367405 of rabbit CTR, and CTR(363412,e13), consisting of residues 363383,398412 of rabbit CTR, were synthesized and purified in the Peptide Facility of Tufts Medical School. Peptide identity and purity were verified by mass spectrometry and NMR. For the CTR (367405) peptide, the two cysteine residues, C392 and C394, were replaced with aminobutyric acid, a common isostere for Cys and represented by a B in the figures.
NMR Methods
CTR (367405) and CTR(363412,e13) were examined (1.4 mM, 9:1 H2O/2H2O, pH 4.3) in the presence of DPC micelles [200 mM DPC-d38 from Cambridge Isotope Laboratories, Inc. (Andover, MA)] and sodium dodecyl sulfate (SDS) (160 mM SDS-d25). All experiments were recorded on a Bruker (Billerica, MA) AVANCE spectrometer (600 MHz) and at temperatures varying between 12 and 45 C. Data processing utilized XWIN-NMR software (Bruker) or NMRPipe (34). Chemical shifts were referenced to the signal of tetramethyl silane (TMS, 0.0 ppm). The proton resonances were identified following standard procedures using double quantum-filtered correlation spectroscopy, total correlation spectroscopy (mixing times = 30, 70 msec), and NOESY (mixing times = 100, 150, 200 msec). Suppression of the solvent signal was achieved by WATERGATE (35).
Radical-Induced Relaxation
The 5- and 16-doxylstearic acid were solubilized in methanol-d4 to a final concentration of 53 mM. Aliquots of this solution were added to the solution of peptide and DPC to obtain 0.250.94 mM concentrations of the spin-label. The titrations with 5- and 16-doxylstearic acid were carried out separately on two equivalent peptide solutions. TOCSY experiments (mixing time 35 msec) were recorded under identical conditions before and after the addition of the doxylstearic acid. The intensities of cross-peaks involving both backbone (HN-H) and side chain protons (H
-Hß, H
-H
) were compared.
Distance Geometry
The NOESY spectra acquired with a mixing time of 200 msec (temperature = 25, 35 C) were used to measure cross-peak volumes that were converted to distances using the two-spin approximation and a ß1/ ß2 cross-peak set to a distance of 1.78 Å. Addition and subtraction of 10% to the calculated distances yielded upper and lower bounds used in the distance geometry calculations. A home-written program, based on the random metrization algorithm of Havel (36), was used to calculate an ensemble of 100 structures following previously published procedures (15).
Molecular Dynamics
MD simulations were performed with GROMACS (37) interactive modeling using Insight II (Biosym Technologies Inc., San Diego, CA). A two-phase box of water and decane was used to mimic the aqueous/hydrophobic phases of the lipid-micelle environment used for the spectroscopic studies, following previously published procedures (15). One of the low-violation distance geometry structures was used as the starting structure for the MD simulation. The molecule was placed in the (periodic) two-phase box of H2O/decane, containing 992 water and 123 decane molecules in a volume of 101.6 nm3. The system was energy-minimized for 100 steps (steepest descent). In the next 10 psec of MD at 27 C, the peptide was restrained to its original position with a force constant of 1000 kJ mol1 nm1. Experimental distance restraints were then introduced with a force constant of 10,000 kJ mol1 nm1 for the 400 psec of the simulation.
Cell Culture and Transient Transfections
DMEM and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA). Media were supplemented with 100 µg/ml streptomycin and 100 U/ml penicillin. HEK 293 cells were cultured as described before (38). For transient transfections, cells were grown to 6070% confluence and then transfected with Fugene 6 (Roche, Mannheim, Germany) according to the protocol of the manufacturer. When not otherwise described, experiments that involved transfection of CTR isoforms alone or in combination were performed with constant amounts of each cDNA and adding empty vector DNA when only one CTR isoform was expressed to keep the total amount of DNA constant.
DNA Constructs
cDNAs encoding the C1a and e13 splice isoforms of the rabbit CTR with a 3-fold FLAG-tag or GFP at the C terminus were generated as described before (16). A fragment spanning the complete receptor including the seventh TMD but lacking the cytoplasmic C-terminal tail of the receptor [amino acids (aa) 1397] was cloned in the KpnI/HindIII site of the pEGFP-N1 vector and designated C1a
397-GFP. Similarly, a fragment spanning the complete receptor up to the N-terminal of the seventh TMD (aa 1374) was generated by PCR and cloned in the KpnI/HindIII site of the pEGFP-N1 vector and the p3XFLAG-CMV-13 vector and designated C1a
374-GFP and C1a
374-FLAG, respectively. All constructs contained an HA-tag in the extracellular N terminus of the receptor (after aa 29 of the original sequence). All PCR-derived constructs were sequenced by the Yale Keck Sequencing Facility.
Coimmunoprecipitation and Western Blotting
Cells were lysed in modified radioimmunoprecipitation assay buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Igepal CA-630 (Sigma) 1% sodium deoxycholate, 10 mM NaF, 1 µg/ml pepstatin, and 1 mM phenylmethanesulfonyl fluoride] and incubated at 4 C for 30 min. Lysates were then centrifuged for 30 min at 4 C, 16,000 x g, the protein concentrations were measured with the bicinchoninic acid protein assay kit (Pierce, Rockford, IL) and equal amounts of protein were used for immunoprecipitation. Thirty microliters of protein G-agarose slurry and typically 5 µg of antibody were suspended in 500 µl PBS and incubated for 1 h at 4 C. The beads were washed three times in modified radioimmunoprecipitation assay buffer, then 500 µg of protein lysate and BSA (0.2% wt/vol) were added, and the mix was incubated for 2 h at 4 C. The immune complexes on the beads were washed four times with washing buffer containing 300 mM NaCl and 0.1% Triton X-100, and once with PBS. Beads were boiled in 2x SDS-PAGE sample buffer and samples were electrophoresed on precast 10% SDS-PAGE gels (Invitrogen). Proteins were transferred to nitrocellulose membranes and the transfer was verified by staining with 0.2% Ponceau S in 3% trichloroacetic acid. Nonspecific binding was blocked by incubating the membranes in 5% nonfat milk in TBST buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Tween 20) for 1 h. Membranes were incubated in the primary antibody in TBST for 2 h, washed three times for 15 min in TBST, and incubated for 1 h in 1:10,000 diluted horseradish peroxidase-conjugated antimouse IgG or antirabbit IgG antibody (Promega) in TBST. Blots were developed using the enhanced chemiluminescence system from Amersham.
Measurement of Receptor Cell Surface Expression by FACS Analysis
Cells in six-well plates were incubated with trypsin-EDTA solution at room temperature. All further steps were performed at 4 C. The trypsin activity was neutralized by addition of growth medium containing 10% dialyzed fetal bovine serum. Cells were collected by centrifugation at 800 x g for 3 min. The cell pellet was resuspended in 100 µl ice-cold PBS. Usually about 3 x 105 cells were used for each experiment. Normal goat IgG was added to a final concentration of 200 µg/ml. After 10 min, the antibody against the N-terminal HA-tag or C-terminal GFP, as indicated in the text, was added to a final concentration of 10 µg/ml. A 30-min incubation step was followed by resuspending in 100 µl PBS containing 50 µg/ml PE-conjugated goat antimouse IgG antibody (Molecular Probes, Eugene, OR). After a final washing step, cells were resuspended in PBS containing 2% formaldehyde to fix the sample. Bound antibody was analyzed by fluorescence flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ). Win MDI software version 2.8 was used for data analysis.
cAMP Measurement
cAMP was measured as described before (9). Cells transfected with the CTR constructs were plated in a 96-well plate (8000 per well). Cells were preincubated with 1 mM of 3-isobutyl-1-methyl-xanthine (Sigma) for 10 min before stimulation with sCT for 10 min at 37 C. The reaction was stopped with 95% ethanol containing 3 mM HCl. cAMP was measured by scintillation proximity assay (Amersham) following the manufacturers instructions.
Measurement of [Ca2+]i
Transfected cells were seeded on glass-bottom dishes. Twenty-four hours later, cells were loaded with 6 µM Fluo-4 by incubation for 30 min at 37 C in conditioned medium. Cells were transferred to a heated perfusion chamber in a confocal microscope and perfused with Na+-HEPES-buffer [135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM glucose, and 20 mM HEPES (pH 7.3), 290 mOsmol/liter]. The chamber was maintained at 37 C and perfused with 1 nM or 10 nM sCT to stimulate the CTR. Intracellular calcium mobilization was monitored using excitation at 468 nm and detection of the emission at 505530 nm. The fluorescence of at least three cells was measured for each construct in each of eight identical experiments.
Statistics
For the FACS analyses, the statistical significance of the differences in PE fluorescence values relative to the fluorescence of cells expressing only C1a was determined by Students t test or by ANOVA followed by a Bonferroni test, as indicated in the figure legends. For the measurements of cAMP production, the statistical significance was determined by ANOVA followed by a Tukeys test.
![]() |
FOOTNOTES |
---|
First Published Online April 28, 2005
Abbreviations: aa, Amino acid; [Ca2+]i, cytosolic free Ca2+; CRH-R1, CRH receptor; CT, calcitonin; CTR, CT receptor; DPC, dodecylphosphocholine; FACS, fluorescence-activated cell sorter; GFP, green fluorescent protein; GPCR, G protein-coupled receptor; HA, hemagglutinin; HEK, human embryonic kidney; MD, molecular dynamics; NMR, nuclear magnetic resonance; NOESY, nuclear Overhauser enhancement spectroscopy; PE, phycoerythrin; sCT, salmon CT; SDS, sodium dodecyl sulfate; TMD, transmembrane domain.
Received for publication November 23, 2004. Accepted for publication April 20, 2005.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |